Your reasoning about being hesitant to test makes no sense.
In 2023 , we are no better at treating advanced cancer than we were 50 years ago. With a very few exceptions, once a cancer is metastasised , the prognosis is quite bad.
On the other hand, we have gotten quite good at detecting cancer early and when detected early, if you can cut it off, your prognosis is really good.
Sadly, we are still on the "wait for symptoms " protocol. If a cancer is big enough to cause symptoms, it is often very hard to treat. Chemo works, but works better when you have less cancer cells. Take a solid cancer, ovarian for example since it is relevant to you. A 1 cm cancer has about 100 million cells whereas a 1 mm cancer has about 100 thousand cells. The chances of not targeting all cancer cells is way greater in a 1 cm cancer. CT and ultrasound cannot really detect cancers smaller than 3 mm.
Ovarian cancer is quite unusual because in many cases, early cancer and advanced cancer have an inverted size. Early cancer remains local and can grow big (even 10 cm) within the ovary. It is not rare for advanced cancer to be way smaller (let's say 4 cm) but this is because it is seeding out of the ovary . Therefor size in ovarian cancer is not always a good predictor of severity.
This brings us back to assessing individual risk. Protocols are made at population level not individual level and your GP is following the national guidelines.
Knowing if you have or not a tumour inducing genetic mutation can change this because then you fall into specific early detection protocols. A mutation is not a ticking bomb. Genes are the gun, and many things can activate or block the trigger. You can then adapt life style (smocking, alcohol, excess weight increase risk of ovarian cancer), have a personalised screening protocol, prophylactic surgery and so on.
There are 84 cancer inducing gene mutations . Some are very organ-specific such as CDKN2A for melanoma, other such as Nf1 or TP53 are multi organ.
For ovarian cancer, there are 21 genes
ATM BARD1 BRCA1 BRCA2 BRIP1 CDH1 CHEK2 DICER1 EPCAM MLH1 MSH2 MSH6 NF1 PALB2 PMS2 PTEN RAD51C RAD51D SMARCA4 STK11 TP53
You can test privately for those. Price will depend on provider. A US based one will be way cheaper.
We now know that more than 95% of ovarian cancers originate in the Fallopian tube. A bilateral salpingectomy is an effective, safe way to greatly reduce your risk of ovarian cancer without inducing menopause. This is an option one would opt for in case of positive genetic testing.
https://www.genturis.eu/l=eng/Home.html is a good website if you want to learn more about genetic tumour risk syndromes.
We need to change our mentality on how we approach cancer risk management.